Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

被引：0
作者：
Jing Zhang
Xueying Lu
Jianyong Li
Yi Miao
机构：
[1] the First Affiliated Hospital of Nanjing Medical University,Department of Hematology
[2] Jiangsu Province Hospital,National Clinical Research Center for Hematologic Diseases
[3] Key Laboratory of Hematology of Nanjing Medical University,undefined
[4] Pukou CLL Center,undefined
[5] the First Affiliated Hospital of Soochow University,undefined
来源：
Biomarker Research | / 10卷
关键词：
BTK inhibitors; BCL2 inhibitors; Chronic lymphocytic leukemia; Mantle cell lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in multiple clinical trials. The second-generation BTK inhibitors, including acalabrutinib and zanubrutinib, also show remarkable efficacies. However, using BTK inhibitors as monotherapies requires continuous treatment. Resistance to BTK inhibitors and severe side effects unavoidably occur during BTK inhibitor monotherapy, frequently resulting in treatment failure. The addition of the BCL2 inhibitor venetoclax to BTK inhibitor may improve the therapeutic effects and result in deeper responses, providing a potential fixed-duration treatment, especially for patients with CLL. In this review, by focusing on CLL and MCL, we discussed the rationale for the combinational use and summarized the current data on the combinations of BTK inhibitors and venetoclax in patients with CLL and MCL.
引用
收藏
相关论文
共 401 条
[1]  
Wang ML(2013)Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma N Engl J Med 369 507-516
[2]  
Rule S(2014)Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 371 213-223
[3]  
Martin P(2015)Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia N Engl J Med 373 2425-2437
[4]  
Goy A(2019)Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 20 43-56
[5]  
Auer R(2018)Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL N Engl J Med 379 2517-2528
[6]  
Kahl BS(2019)Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia N Engl J Med 381 432-443
[7]  
Byrd JC(2016)Second-generation inhibitors of Bruton tyrosine kinase J Hematol Oncol 9 80-745
[8]  
Brown JR(2016)Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor J Hematol Oncol 9 21-1363
[9]  
O'Brien S(2021)Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies J Hematol Oncol 14 40-798
[10]  
Barrientos JC(2015)Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results Blood. 126 739-2719
12345678910